Estimating the lives that could be saved by expanded access to weight- loss drugs

• 成果类型: Article
• 署名作者: Pandey, Abhishek; Ye, Yang; Wells, Chad R.; Singer, Burton H.; Galvani, Alison P.
• 署名单位: Yale University; State University System of Florida; University of Florida
• 刊物名称: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
• ISSN/ISSBN: 0027-8570
• DOI: 10.1073/pnas.2412872121
• 发表日期: 2024-10-22
• 关键词: body-mass index; mortality

摘要

population, exacerbating a spectrum of other diseases and contributing significantly to morbidity and mortality overall. Recent advances in pharmaceutical interventions, tirzepatide), have shown remarkable efficacy in weight- loss. However, limited access to these medications due to high costs and insurance coverage issues restricts their utility in mitigating the obesity epidemic. We quantify the annual mortality burden directly attributable to limited access to these medications in the US. By integrating hazard ratios of mortality across body mass index categories with current obesity prevalence data, combined with healthcare access, willingness to take the medication, and observed adherence to and efficacy of the medications, we estimate the impact of making these medications accessible to all those eligible. Specifically, we project that with expanded access, over 42,000 deaths could be averted annually, including more than 11,000 deaths among people with type 2 diabetes. These findings underscore the urgent need to address barriers to access and highlight the transformative public health impact that could be achieved by expanding access to these novel treatments.